Skip to main content

Table 1 Demographic and disease characteristics of AS patients treated with ETN and ADA, respectively

From: An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus

  ADA- and ETN-treated AS patients (n = 31) ETN-treated AS patients (n = 15) ADA-treated AS patients (n = 16)
Demographics
 Sex (M:F) 22:9 11:4 11:5
 Age (years) 38 ± 10.2 37.7 ± 11.5 38.3 ± 9.2
Disease status
 DD (months) 140.8 ± 117.9 145.1 ± 135.4 136.8 ± 103.8
 BASDAI at baseline 6.2 ± 1.3 6.2 ± 1.5 6.2 ± 1.2
 BASDAI red. (%) 47.6 ± 31.3 51.1 ± 31.7 44.3 ± 31.6
 BASDAI assessment (months) 3.1 ± 1.4 3 ± 1 3.2 ± 1.6
 BASDAI50 (R:NR) 19:12 10:5 9:7
 CRP (mg/dl) 1.5 ± 1.7 1.3 ± 1.1 1.6 ± 2.2
 HLA-B27-positive (%) 81 87 75
 ESR (mm/h) 33.2 ± 21.9 31.7 ± 22.3 34.6 ± 22.3
  1. Results are displayed as mean ± SD unless otherwise indicated
  2. ADA adalimumab, AS ankylosing spondylitis, BASDAI Bath Ankylosing Disease Activity Index, BASDAI red. percental BASDAI reduction after 1–6 month of therapy, BASDAI50 percental BASDAI reduction according to an improvement of 50%, CRP C-reactive protein, DD disease duration, ESR erythrocyte sedimentation rate, ETN etanercept, F female, HLA human leukocyte antigen, M male, NR non-responder, R responder